Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
- ISSN: 08966273
- ISBN: 1097-4199 (Electronic)\n0896-6273 (Linking)
- DOI: 10.1016/j.neuron.2012.03.009
- PubMed: 22500629
Fragile X syndrome (FXS) is the most common form of inherited intellectual disability. Previous studies have implicated mGlu5 in the pathogenesis of the disease, but a crucial unanswered question is whether pharmacological mGlu5 inhibition is able to reverse an already established FXS phenotype in mammals. Here we have used the novel, potent, and selective mGlu5 inhibitor CTEP to address this issue in the . Fmr1 knockout mouse. Acute CTEP treatment corrects elevated hippocampal long-term depression, protein synthesis, and audiogenic seizures. Chronic treatment that inhibits mGlu5 within a receptor occupancy range of 81% ± 4% rescues cognitive deficits, auditory hypersensitivity, aberrant dendritic spine density, overactive ERK and mTOR signaling, and partially corrects macroorchidism. This study shows that a comprehensive phenotype correction in FXS is possible with pharmacological intervention starting in young adulthood, after development of the phenotype. It is of great interest how these findings may translate into ongoing clinical research testing mGlu5 inhibitors in FXS patients. Michalon et al. provide evidence that mGlu5 antagonists have disease-modifying potential for Fragile X syndrome, showing that pharmacological inhibition of mGlu5 in adult mice, after disease onset, corrects a wide spectrum of FXS symptoms in these animals. © 2012 Elsevier Inc.